Given that the binding of S100A9 to RAGE in the cancer cell is the trigger to the activation of nuclear factor kappa B (NF-κB) signaling and JunB, which underlies the resistance mechanism to radiotherapy, this therapeutic approach paradoxically desensitizes metastatic cells to it. Here, AGER is linked to cancer.